David Tischler Email & Phone Number
@neutrolis.com
LinkedIn matched
Who is David Tischler? Overview
A concise factual answer block for searchers comparing this professional profile.
David Tischler is listed as Co-Founder and CEO at CureTrust, based in San Francisco, California, United States. AeroLeads shows a work email signal at neutrolis.com and a matched LinkedIn profile for David Tischler.
David Tischler previously worked as Business Advisor at Neutrolis Inc and Advisor at Nosis Bio. David Tischler holds Master Of Business Administration (M.B.A.) from University Of California, Berkeley, Haas School Of Business.
Email format at CureTrust
This section adds company-level context without repeating David Tischler's masked contact details.
AeroLeads found 1 current-domain work email signal for David Tischler. Compare company email patterns before reaching out.
About David Tischler
Life science executive and entrepreneur. Broad life science and healthcare experience as an operator and investor including new company development. Currently engaged by VC firms and their portfolio companies to help with NewCo development, financing, business development (in-licensing, out-licensing, partnerships, collaborations), corporate development and product management. Strive to be a force multiplier and build scalable, innovative life science organizations with a focus on therapeutics, gene therapy, techbio / bio-IT, and digital health.
Listed skills include Strategic Partnerships, Venture Formation, Start Ups, Biotechnology, and 20 others.
David Tischler's current company
Company context helps verify the profile and gives searchers a useful next step.
David Tischler work experience
A career timeline built from the work history available for this profile.
Business Advisor
CurrentDeveloping first-in-class therapies for autoimmune and inflammatory diseases by targeting neutrophil extracellular traps (NETs). Recently named by VCs as 1 of 24 biotech startups poised to take off (Business Insider - August 2021).
Advisor
CurrentDelivering on the promise of RNA medicines leveraging foundational generative AI models, protein engineering and multiplexed in vitro and in vivo capabilities
Advisor | Strategy And Operations Consultant
CurrentNovel AAV capsid development to better deliver the promise of gene therapy
Advisor | Strategy And Operations Consultant
CurrentNext generation boron neutron capture therapy (BNCT) company seeking to transform oncology care with best-in-class therapeutics, neutron accelerators, and patient positioning.
Advisor
CurrentKdT Ventures invests in early stage companies commercializing frontier science
Tischler Bioconsulting
CurrentEngaged by VC firms and their portfolio companies to help with financing, business development, corporate development and product management. Advise therapeutics, TechBio / AI, and digital medicine companies solving large unmet needs with transformative innovations. Project Areas: Biologics, Gene Therapy, Cell Therapy, Artificial Intelligence, Quantum.
Ceo & Co-Founder
ZetaGen Therapeutics (formerly Fusologics), is an early stage life science company developing therapeutic solutions for large unmet needs in the regenerative medicine and oncology markets. Co-founded company, built therapeutics / combination product pipeline and led strategy, financing and operations. ZetaGen was selected to the 2018 cohort of the.
Product Manager
Worked on Castlight's (NYSE: CSLT) Action product, which leverages machine learning, targeted messaging and innovative behavior modification to empower employees of Fortune 500 company to make high quality, high value healthcare decisions. Led creation of scalable experimentation infrastructure, implementation of product analytics and development of.
Ceo (Interim)
Served as acting CEO for DigiSight. Before rebranding as Verana, DigiSight was a digital health company that created a mobile vision monitoring platform to track ophthalmic disease progression and connect patients to their physicians. Founded by thought-leading ophthalmologists, DigiSight leveraged the cloud and innovative mobile technology to enable.
Due Diligence Chair
Associate
Venzyme buillds financiable, innovative companies around early stage life science technologies.
Research Scientist
Investigating the mechanisms behind pancreatitis and pancreatic cancer in Dr. Stephen Pandol's Pancreatic Research Group. Second Author on Gastroenterology Paper: "Adaptive unfolded protein response attenuates alcohol-induced pancreatic damage. Gastroenterology. 2011 Mar;140(3):987-97. doi: 10.1053/j.gastro.2010.11.038.
David Tischler education
Master Of Business Administration (M.B.A.)
Bs, Biology
Sigm
Frequently asked questions about David Tischler
Quick answers generated from the profile data available on this page.
What company does David Tischler work for?
David Tischler works for CureTrust.
What is David Tischler's role at CureTrust?
David Tischler is listed as Co-Founder and CEO at CureTrust.
What is David Tischler's email address?
AeroLeads has found 1 work email signal at @neutrolis.com for David Tischler at CureTrust.
Where is David Tischler based?
David Tischler is based in San Francisco, California, United States while working with CureTrust.
What companies has David Tischler worked for?
David Tischler has worked for Curetrust, Neutrolis Inc, Nosis Bio, Apertura Gene Therapy, and Aviko Radiopharmaceuticals.
How can I contact David Tischler?
You can use AeroLeads to view verified contact signals for David Tischler at CureTrust, including work email, phone, and LinkedIn data when available.
What schools did David Tischler attend?
David Tischler holds Master Of Business Administration (M.B.A.) from University Of California, Berkeley, Haas School Of Business.
What skills is David Tischler known for?
David Tischler is listed with skills including Strategic Partnerships, Venture Formation, Start Ups, Biotechnology, Market Research, Healthcare, Life Sciences, and Competitive Analysis.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial